Oncology

Eric D. Whitman, MD, discusses the clinical trial program at Atlantic Health System, a large nonprofit health care network in New Jersey, and how partnering with the Translational Genomics Research Institute will help to bring better care to patients with cancer.

CancerNetwork® sat down with C. Jillian Tsai, MD, PhD, at the 2021 American Society for Radiation Oncology to talk about why consolidative radiotherapy may be beneficial against oligoprogression in metastatic breast and lung cancer.

Join ASTCT for a series of webinars that focus on topics relating to CAR T.

CancerNetwork® spoke with Anthony W. Tolcher, MD, and Alexander I. Spira MD, PhD, about NEXT Oncology partnering with the Phase 1 Trials Program at Virginia Cancer Specialists to give patients another chance at treatment.

ASTCT recently published an article in their journal Nucleus detailing a simplified manufacturing process for CAR T cells.

The AVENIO Tumor Tissue Comprehensive Genomic Profiling Kit could allow for more accessible genetic testing and result in more personalized treatments.

Investigators believe that a systems-based intervention could reduce or even eliminate racial gaps in cancer treatment completion and improve outcomes.

Roy S. Herbst, MD, PhD, shares insight on approaching clinical decision-making for the length of immunotherapy treatment and drug holidays for patients with NSCLC.

An expert in thoracic oncology provides an overview of ctDNA and discusses what ctDNA testing results can indicate about a patient’s likelihood of responding to immunotherapy in NSCLC.

In a debate, experts discuss the importance of IGHV and TP53 mutational status in predicting response to novel therapies in chronic lymphocytic leukemia.

Roy S. Herbst, MD, PhD, reviews indicators of relapse or progression of disease when monitoring patients on therapy in NSCLC.

Roy S. Herbst, MD, PhD, provides insight on selecting the optimal therapy for non–small-cell lung cancer and shares considerations for the use of combination chemotherapy and immunotherapy.

“In my mind, the question is not who should get chemotherapy, but who can avoid chemotherapy in this day and age.”

Josh Ludwig detailed to CancerNetwork® how ScaleReady can help make cell and gene therapy widely practical and viable for patients with cancer.

Patients with solid tumors and an NTRK gene fusion who experienced progressive disease appear to derive benefit from repotrectinib, which received a breakthrough therapy designation from the FDA.

Patients with early breast cancer appear to have consistent prognostic value associated with residual cancer burden, regardless of disease subtype.

Solange Peters, MD, PhD, detailed several important abstracts from the Presidential Symposia at the 2021 ESMO Congress she believes will be practice changing.

Several factors among cancer survivors, such as rural residence, low income, and low education were found to be independently associated with a higher risk of developing new-onset cardiovascular disease.

Although safety, efficacy, and symptom burden were not statistically different between patients with pulmonary oligometastases treated with single- or multi-fraction stereotactic ablative body radiotherapy, delivery appeared more efficient in the single-fractionation arm.

CancerNetwork speaks with Josh Ludwig on its latest podcast to discuss ScaleReady’s plans to make cell and gene therapy more practical and viable moving forward.

Marshall Posner, MD, detailed the potential for personalized mRNA vaccines to treat patients with various different tumors and what information is still needed.

By not including race as part of the Chronic Kidney Disease-Epidemiology Collaboration equation, Black patients with cancer were more likely to not receive treatment for their disease.

ESMO’s president, Solange Peters, MD, PhD, discussed a handful of key abstracts presented during the 3 Presidential Symposia sessions at the 2021 ESMO Congress.

A phase 2 trial did not find a significant benefit to progression-free survival with regorafenib in patients with advanced or metastatic chrodoma.

CancerNetwork® sat down with Jason Luke, MD, at the 2021 European Society for Medical Oncology Congress to talk about the latest developments in the use of immunotherapy for metastatic disease.

The toxicity profiles of PD-1 and PD-L1 inhibitors displayed unique characteristics when combines with other agents such as chemotherapy, targeted therapy, and immunotherapy.

Data from the Circulating Cell-Free Genome Atlas on Clinical limit of detection, or cLOD, may help investigators better detect multiple cancers at earlier stages.

The latest episode of CancerNetwork®’s podcast examines an initiative to diversify patient populations in oncology clinical trials and increase accessibility to these opportunities.

Elizabeth Comen, MD, discusses how she balances her love of dance with both her family and her career as a breast cancer oncologist.